A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia.
T‐cell large granular lymphocytic leukemia
decitabine
frail patients
non‐cytotoxic regimen
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
05
05
2021
revised:
04
06
2021
accepted:
14
06
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
We report on a novel, successful, non-cytotoxic therapy to treat multiply-refractory T-LGL in an elderly patient.
Identifiants
pubmed: 34552731
doi: 10.1002/ccr3.4533
pii: CCR34533
pmc: PMC8443408
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e04533Informations de copyright
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
YS has equity in EpiDestiny. There is no financial and research support. YS received intellectual property—patents around tetrahydrouridine, decitabine, and 5‐azacytidine (US 9,259,469 B2; US 9,265,785 B2; US 9,895,391 B2) and cancer differentiation therapy (US 9,926,316 B2).
Références
Acta Haematol. 2021;144(1):95-99
pubmed: 32348994
Leukemia. 2020 Mar;34(3):957-962
pubmed: 31624375
Am J Hematol. 2021 Jul 1;96(7):772-780
pubmed: 33819354
Am Soc Clin Oncol Educ Book. 2018 May 23;38:616-625
pubmed: 30231346
Br J Haematol. 2020 Mar;188(6):924-929
pubmed: 31736067
Leukemia. 2020 Apr;34(4):1116-1124
pubmed: 31740810
J Clin Invest. 2015 Mar 2;125(3):1043-55
pubmed: 25621498
Hum Pathol. 2018 Mar;73:74-81
pubmed: 29288042
Blood. 2013 May 9;121(19):3843-54, S1
pubmed: 23515927
Blood. 2003 Dec 1;102(12):3865-70
pubmed: 12907443
Leuk Lymphoma. 2018 Feb;59(2):416-422
pubmed: 28633612
Hematology Am Soc Hematol Educ Program. 2013;2013:511-21
pubmed: 24319226
Blood. 2017 Mar 2;129(9):1082-1094
pubmed: 28115367
Ann Intern Med. 1985 Feb;102(2):169-75
pubmed: 3966754